ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Recruiting now · Phase 2
Conditions studied: Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets Type 2
In brief
The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
Key facts
- Study ID
- NCT06462547
- Run by
- Inozyme Pharma
- People needed
- 200
- Starts
- 2024-06-19
- Expected to finish
- 2030-12-01
- Last updated by the study team
- 2024-11-29
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States (enrolling)
- Clinilabs Drug Development Corporation — Eatontown, New Jersey, United States (enrolling)
- Necker-Enfants Malades Hospital — Paris, France (enrolling)
- Universitätsklinikum Hamburg-Eppendorf (UKE) — Hamburg, Germany (enrolling)
- VCTC — Oxford, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.